质子泵抑制剂与慢性丙型肝炎感染非肝硬化患者肝硬化、肝功能失代偿及肝细胞癌加速发展的相关性:ERCHIVES研究结果
基于ERCHIVES数据库纳入11526例接受丙型肝炎治疗的感染者,用累积限定日剂量衡量质子泵抑制剂暴露。多因素Cox回归显示,质子泵抑制剂暴露与肝硬化(HR 1.32)、肝功能失代偿(HR 3.79)及肝细胞癌(HR 2.01)风险升高独立相关,且呈剂量依赖性。
要点
- 在慢性HCV感染非肝硬化患者中,质子泵抑制剂暴露与肝硬化风险升高独立相关(HR 1.32)。
- 质子泵抑制剂暴露与肝功能失代偿(HR 3.79)及肝细胞癌(HR 2.01)风险升高独立相关。
- 质子泵抑制剂使用增加与慢性肝病向肝硬化进展呈剂量依赖性风险相关。
核心结论
- 在慢性HCV感染患者中,质子泵抑制剂使用增加与慢性肝病进展至肝硬化的剂量依赖性风险相关,并与肝功能失代偿和肝细胞癌风险升高相关。
研究设计与样本
- 利用电子检索的HCV感染退伍军人队列(ERCHIVES)数据库,识别所有接受HCV治疗者及所有肝硬化、肝功能失代偿和肝细胞癌 incident 病例。
- 质子泵抑制剂使用以累积限定日剂量衡量。
- 在校正肝硬化的单因素预测因子及质子泵抑制剂各种使用指征后,进行多因素Cox回归分析。
- 共纳入11526例符合条件的个体。
主要发现
- 质子泵抑制剂暴露与肝硬化风险升高独立相关(HR 1.32;95%CI 1.17–1.49)。
- 仅分析达到持续病毒学应答的患者以及排除酒精滥用/依赖者的敏感性分析中,该关联仍然稳健。
- 质子泵抑制剂暴露与肝功能失代偿风险升高独立相关(HR 3.79;95%CI 2.58–5.57)。
- 质子泵抑制剂暴露与肝细胞癌风险升高独立相关(HR 2.01;95%CI 1.50–2.70)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton pump inhibitors are among the most commonly prescribed medications in the United States. Their safety in cirrhosis has recently been questioned, but their overall effect on disease progression in noncirrhotic patients with chronic liver disease remains unclear. AIM: To determine the impact of proton pump inhibitors on the progression of liver disease in noncirrhotic patients with hepatitis C virus (HCV) infection. METHODS: Using the electronically retrieved cohort of HCV-infected veterans (ERCHIVES) database, we identified all subjects who received HCV treatment and all incident cases of cirrhosis, hepatic decompensation and hepatocellular carcinoma. Proton pump inhibitor use was measured using cumulative defined daily dose. Multivariate Cox regression analysis was performed after adjusting univariate predictors of cirrhosis and various indications for proton pump inhibitor use. RESULTS: Among 11 526 eligible individuals, we found that exposure to proton pump inhibitors was independently associated with an increased risk of developing cirrhosis (hazard ratio [HR]: 1.32; 95% confidence interval: [1.17, 1.49]). This association remained robust to sensitivity analysis in which only patients who achieved sustained virologic response were analysed as well as analysis excluding those with alcohol abuse/dependence. Proton pump inhibitor exposure was also independently associated with an increased risk of hepatic decompensation (HR: 3.79 [2.58, 5.57]) and hepatocellular carcinoma (HR: 2.01 [1.50, 2.70]). CONCLUSIONS: In patients with chronic HCV infection, increasing proton pump inhibitor use is associated with a dose-dependent risk of progression of chronic liver disease to cirrhosis, as well as an increased risk of hepatic decompensation and hepatocellular carcinoma.
引用
- Li DK, Yan P, Abou-Samra AB, et al. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther. 2017. PMID: 29105111. doi:10.1111/apt.14391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。